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Objective: The PREVENT III study was a prospective, randomized, double-blinded, multicenter phase III trial of a novel
molecular therapy (edifoligide; E2F decoy) for the prevention of vein graft failure in patients undergoing infrainguinal
revascularization for critical limb ischemia (CLI).
Methods: From November 2001 through October 2003, 1404 patients with CLI were randomized to a single intraoper-
ative ex vivo vein graft treatment with edifoligide or placebo. After surgery, patients underwent graft surveillance by
duplex ultrasonography and were followed up for index graft and limb end points to 1 year. A blinded Clinical Events
Classification committee reviewed all index graft end points. The primary study end point was the time to nontechnical
index graft reintervention or major amputation due to index graft failure. Secondary end points included all-cause graft
failure, clinically significant graft stenosis (>70% by angiography or severe stenosis by ultrasonography), amputation/
reintervention-free survival, and nontechnical primary graft patency. Event rates were based on Kaplan-Meier estimates.
Time-to-event end points were compared by using the log-rank test.
Results:Demographics, comorbidities, and procedural details reflected a population with CLI and diffuse atherosclerosis.
Tissue loss was the presenting symptom in 75% of patients. High-risk conduits were used in 24% of cases, including an
alternative vein in 20% (15% spliced vein and 5% non–great saphenous vein) and 6% less than 3 mm in diameter; 14% of
the cases were reoperative bypass grafts. Most (65%) grafts were placed to infrapopliteal targets. Perioperative (30-day)
mortality occurred in 2.7% of patients. Major morbidity included myocardial infarction in 4.7% and early graft occlusion
in 5.2% of patients. Ex vivo treatment with edifoligide was well tolerated. There was no significant difference between the
treatment groups in the primary or secondary trial end points, primary graft patency, or limb salvage. A statistically
significant improvement was observed in secondary graft patency (estimated Kaplan-Meier rates were 83% edifoligide and
78% placebo; P .016) within 1 year. The reduction in secondary patency events was manifest within 30 days of surgery
(the relative risk for a 30-day event for edifoligide was 0.45; 95% confidence interval, 0.27-0.76; P  .005). For the
overall cohort at 1 year, the estimated Kaplan-Meier rate for survival was 84%, that for primary patency was 61%, that for
primary assisted patency was 77%, that for secondary patency was 80%, and that for limb salvage was 88%.
Conclusions: In this prospective, randomized, placebo-controlled clinical trial, ex vivo treatment of lower extremity vein
grafts with edifoligide did not confer protection from reintervention for graft failure. ( J Vasc Surg 2006;43:742-51.)Autologous vein remains the best-performing conduit
for small-caliber arterial reconstructions. However, the ar-
terialized vein is subject to a spectrum of hemodynamic,
inflammatory, and humoral mechanisms of injury that may
induce pathologic changes.1,2 Such changes are responsible
for a significant incidence of vein graft stenosis or occlusion,
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been a primary target of experimental therapies designed to
improve long-term bypass graft function.
Smooth muscle cell (SMC) proliferation is a key feature
of neointimal lesions in veins and arteries, and much effort
has focused on understanding SMC growth control at the
molecular level. The transcription factor E2F plays a critical
role in coordinating the expression of several genes that
regulate cell-cycle progression, and, therefore, inhibition of
E2F function is expected to block cellular proliferation.6
Recently a new class of molecular therapeutics has been
developed that consists of short double-stranded oligode-
oxynucleotides (ODN) that bear a consensus binding site
for a specific transcription factor. Once delivered into cells,
these ODN can serve as a competitive inhibitor (decoy) to
the transcription factor, thus blocking the activation of the
downstream genes specific to that transcription factor.7,8 A
transcription factor decoy approach was developed to spe-
cifically target E2F and was found to be effective at inhib-
iting SMC proliferation and reducing neointimal hyperpla-
sia in animal models of vascular injury.9 Studies in a rabbit
carotid-jugular interposition graft model demonstrated
that edifoligide (E2F decoy) treatment of the vein at im-
plantation reduced target gene (proliferating cell nuclear
antigen and c-myc) expression and SMC proliferation and
significantly reduced neointimal hyperplasia in the grafts as
compared with controls.10 Studies using human saphenous
veins demonstrated that administration of edifoligide by
using a nondistending pressure device resulted in drug
delivery to approximately 90% of the cells in the vein wall.11
The ability to effectively deliver this therapeutic agent to
vein grafts with a brief (10-minute) ex vivo incubation
protocol, in combination with a positive safety profile and a
lack of other effective therapies to reduce vein graft disease,
led to a series of clinical trials to test edifoligide in human
subjects.
Phase I and II studies conducted in peripheral (PREVENT
I; n  46 patients)11 and coronary (PREVENT II; n  200
patients)12 bypass graft settings suggested that edifoligide treat-
ment of vein graftswas safe and feasible.These studies confirmed
target gene inhibition in the graft wall and suggested a biological
effect.ThePREVENTIII studywasdesigned to test thehypoth-
esis that edifoligide, administered ex vivo to the vein graft just
before implantation, would reduce the incidence of vein graft
failure in patients undergoing lower extremity bypass for the
treatment of chronic limb ischemia.
METHODS
Study design. The Project or Ex-Vivo vein graft En-
gineering via Transfection III (PREVENT III) Study was a
phase III multicenter, randomized, double-blinded, place-
bo-controlled trial of edifoligide for prevention of vein
graft failure in patients undergoing lower extremity revas-
cularization for critical limb ischemia (CLI). Details of the
trial design are reported elsewhere13 and are summarized
here. The study was cosponsored by Corgentech Inc
(South San Francisco, Calif) and Bristol-Myers Squibb
(Princeton, NJ) and was conducted at 83 North Americansites (Appendix I online). Enrollment was initiated in No-
vember 2001 and closed in October 2003.
The primary trial end point was the time to occurrence
of nontechnical index graft failure resulting in either graft
revision or major amputation (ie, transtibial or above)
within 12 months of enrollment. A Clinical Events Classi-
fication (CEC) committee (Appendix II online) performed
a blinded, independent review of each case of index graft
failure to determine a technical or nontechnical etiology
according to prespecified criteria.13 In each case, the CEC
reviewed primary source documents, including hospital
admission and discharge notes, operative notes, and reports
of all index graft imaging studies. For the purposes of this
study, technical graft failure was predefined to exclude
events that were clearly unrelated to the development of
intrinsic vein graft or anastomotic disease (eg, intimal hy-
perplasia).
Technical failures were thus considered to be encom-
passed within one of four possible categories: inadequate
inflow, inadequate outflow, extrinsic lesions, and intrinsic
lesions. For each category, specific diagnostic criteria were
detailed for the CEC in a governing process document and
included factors such as the timing of the event in relation
to the original surgery and the nature of findings reported
by the operating surgeon/interventionalist or interpreting
radiologist. The CEC was guided by a conservative philos-
ophy in the adjudication process, considering failures to be
nontechnical unless they clearly fit these prespecified de-
tailed criteria.
Secondary end points of the study included all-cause
graft failure (ie, technical or nontechnical), nontechnical
primary patency, freedom from clinically significant index
graft stenosis (defined as the first occurrence of any of the
following: 70% stenosis by angiography, severe stenosis or
occlusion by ultrasonography, index graft revision, or major
amputation secondary to index graft failure), and amputation
and index graft failure-free survival. In addition to these pro-
tocol-specified end points, traditional vascular surgery out-
comes such as graft patency and limb salvage were calculated
in accordance with suggested reporting standards.14
Inclusion and exclusion criteria. Patients were eligi-
ble for enrollment if they were at least 18 years of age and
were scheduled to undergo an infrainguinal bypass proce-
dure with an autologous vein conduit for the treatment of
CLI (gangrene, nonhealing ischemic ulcer, or ischemic rest
pain; Rutherford categories 4-6). In patients presenting
with rest pain as their sole symptom, the diagnosis of CLI
was corroborated by at least one of the following hemody-
namic criteria: an ankle systolic pressure of 50 mm Hg or
less, an ankle-brachial index (ABI) of 0.4 or less, a toe
pressure of 30 mm Hg or less, a transcutaneous PO2 of less
than 30 mmHg, or a severely ischemic or flat-line transtar-
sal pulse volume recording. Permissible reconstructions
included reoperative vein grafts, spliced veins, vein grafts
that arose from a prosthetic inflow graft at or above the
femoral bifurcation, and infrainguinal bypass in the setting
of simultaneous inflow (catheter-based or surgical) recon-
structions.
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the indication for bypass, a planned in situ saphenous vein
reconstruction (precluding the graft from ex vivo treatment
in the pressurized drug-delivery device), or a documented
history of a hypercoagulable condition. Revisions of pre-
existing infrainguinal bypass grafts, reconstructions that
used any synthetic or nonautologous component, or vein
grafts attached to a nonautologous graft below the femoral
bifurcation were excluded.
Randomization and study drug administration.
Randomization was performed at the time of operation by
the investigational pharmacy at each participating site. A
1:1 randomization scheme was established by using num-
bered, blinded study drug kits that were supplied to each
site along with a drug dispensation list. Study drug (edifo-
ligide 40 mol/L or placebo [buffered normal saline]) was
administered ex vivo to the vein graft as a single dose in the
operating room after vein harvest and before implantation.
The vein was placed in a specially designed pressurization
chamber (Corgentech pressure-mediated delivery system),
and study drug was infused through the lumen to fill the
chamber and immerse the graft. With drug both inside and
outside of the vein, the chamber was pressurized to 6
pounds per square inch of nondistending pressure for 10
minutes. Subsequently the vein was removed, rinsed, and
flushed in the surgeon’s standard vein bath solution, and
the graft was implanted. A prior clinical study had demon-
strated efficient uptake of the decoy ODN by cells in the
vein wall with this technique.11 Participating surgeons and
operating room assistants were trained on the proper use of
the device by using on-site training sessions, a training
video, and explicit directions for use.
Postoperative care and study assessments. Clinical
laboratories (chemistries, hematology, and urinalysis) were
collected at baseline and at 48 hours after surgery. All
adverse events were recorded through the first 30 days after
surgery, after which rehospitalizations, index limb-related
events, and deaths were recorded through study termina-
tion at 12 months. An independent Data Safety Monitor-
ing Board (Appendix II online) provided safety data at
intervals during the study.
Early graft patency was to be documented either by
intraoperative imaging (contrast angiography or duplex
ultrasonography) or by duplex ultrasonography before dis-
charge. The study protocol mandated intensive postopera-
tive surveillance of the index graft, with duplex ultrasound
imaging at 1, 3, 6, and 12 months after bypass surgery. A
9-month study was also obtained if a flow abnormality was
observed at 6 months. Ultrasound studies were interpreted
and recorded at the individual sites. Physical examination
for vascular status, including an ABI, was conducted at
baseline, on postoperative day 2, and at months 1, 3, 6, 9,
and 12. A quality of life questionnaire (VascuQol15) was
completed before surgery and at 3 and 12 months after
surgery.
Investigators were allowed to use any and all appropri-
ate concomitant medications, both before and after the
procedure, as dictated by their usual clinical practice pat-terns. The protocol discouraged the use of postoperative
anticoagulants (warfarin, heparin, or low-molecular-weight
heparin) solely for the prevention of bypass graft occlusion.
Concomitant medications were recorded at baseline and at
all follow-up study visits.
The protocol specified an algorithm for determining
the need for graft reintervention. The criteria included an
angiographic stenosis of greater than 70%, recurrent symp-
tomatic CLI and an angiographic stenosis of greater than
50%, severe hemodynamic compromise of the index limb
(ABI of0.4 or a toe pressure of30mmHg), or a duplex
ultrasound study indicating severe graft stenosis (a peak
systolic velocity ratio of 3.0 or a peak systolic velocity of
300 cm/s). Angiography (contrast or magnetic reso-
nance) was mandated before elective graft revision, unless
contraindicated. All episodes of index graft occlusion, revi-
sion, or amputation were recorded through month 12 and
submitted to the CEC committee for adjudication.
A pharmacokinetic (PK) substudy was also conducted
at five sites. Thirty-one subjects were enrolled and under-
went blood sampling at baseline (before the treated vein
graft was implanted) and at 5, 10, 30, and 60 minutes and
2, 4, and 24 hours after flowwas initiated through the index
graft.
Statistical methods. The protocol-specified time-to-
event end-point analyses were performed on an intent-to-
treat basis by using the Kaplan-Meier method, and the
treatment groups were compared by using the log rank test.
Other analyses performed (Kaplan-Meier estimates) in-
cluded primary, primary assisted, and secondary graft pa-
tency, as well as limb salvage, defined in accordance with
published standards for outcomes reports in lower extrem-
ity revascularization.14 All statistical tests were performed at
a nominal significance level of .05. No statistical adjustment
was considered for multiplicity of statistical testings.
RESULTS
Characteristics of the study cohort and index sur-
gical procedures. A total of 1404 patients were random-
ized for the efficacy study at the 83 participating trial sites
and make up the intention-to-treat population. Of these
1404 patients, 1138 (563 edifoligide and 575 placebo)
completed the 12-month follow-up. A total of 18 (1.3%)
patients (12 edifoligide and 6 placebo) were lost to follow-
up, and 26 (1.9%) patients (17 edifoligide and 9 placebo)
withdrew from the study. There were 222 deaths (15.8%;
115 edifoligide and 107 placebo) during the year after
enrollment. An additional group of 16 patients were en-
rolled to complete the PK substudy after the intention-to-
treat group was fully enrolled. The safety population for
PREVENT III therefore included 1420 patients. As pre-
specified in the protocol, these additional 16 patients were
followed up only for adverse events for 30 days and were
not included in the efficacy analyses.
Characteristics of the study population (intention-to-
treat) are summarized in Table I and are consistent with
advanced atherosclerosis. Most patients were male (64%),
with a mean (SD) age of 69  12 years. Prevalent comor-
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tes (64%), and hyperlipidemia (55%). Forty-eight percent had
a history of advanced coronary artery disease, including
previous myocardial infarction in 30%, previous coronary
artery bypass in 25%, and previous percutaneous coronary
intervention in 17%. Twenty percent of patients had a
history of stroke or transient ischemic attack (symptomatic
cerebrovascular disease). Previous lower extremity bypass
surgery had been performed in 27% of patients, and 17%
were in the limb contralateral to the index graft. Dialysis-
dependent renal failure was present in 12% of patients at
study entry. The groups were well matched for all of the
comorbidities and baseline demographics.
Seventy-five percent of patients presented with tissue
loss (39% ulcer and 35% gangrene). Diabetic patients were
significantly more likely to present with tissue loss (86% vs
56%; P  .0001). For 16% of patients, the index operation
constituted a reoperative infrainguinal bypass in that limb.
A single-segment vein graft was used in 85% of cases, and
15% required spliced vein grafts. Overall, 20% of cases
Table I. Characteristics of the PREVENT III study
population at baseline
Variable
Edifoligide
(n  707)
Placebo
(n  697)
Age (y)
Mean  SD 68.7  11.68 68.3  11.42
Median 70.0 69.0
Male 454 (64.2%) 443 (63.6%)
Ethnic origin
White 526 (74.4%) 491 (70.4%)
Black 116 (16.4%) 133 (19.1%)
Asian 3 (0.4%) 7 (1.0%)
Hispanic 53 (7.5%) 54 (7.7%)
Other 9 (1.3%) 12 (1.7%)
CLI criterion (worst)
Rest pain 184 (26.0%) 169 (24.2%)
Nonhealing ulcer 273 (38.6%) 280 (40.2%)
Gangrene 247 (34.9%) 246 (35.3%)
Ankle-brachial index
Mean 0.5 0.5
Median 0.4 0.4
Comorbidities
Hypertension 577 (81.6%) 569 (81.6%)
Diabetes 461 (65.2%) 439 (63.0%)
CAD 353 (49.9%) 324 (46.5%)
CVD 144 (20.4%) 140 (20.1%)
Smoking* 520 (73.5%) 513 (73.6%)
Dyslipidemia 393 (55.6%) 373 (53.5%)
Dialysis 84 (11.9%) 86 (12.3%)
Prior leg revascularization†
Inflow 146 (20.7%) 147 (21.1%)
Infrainguinal (either limb) 190 (26.9%) 193 (27.7%)
CLI, Critical limb ischemia; CAD, coronary artery disease (prior myocardial
infarction or surgical or percutaneous revascularization); CVD, cerebrovas-
cular disease (prior stroke or transient ischemic attack).
Data are n (%) unless otherwise noted; P values for all are not significant.
*Smoking includes current or former as self-reported.
†Prior leg revascularization includes either surgical or percutaneous inter-
ventions.required either a spliced or non–great saphenous venousconduit. These conduits, in addition to those having less
than a 3-mm initial diameter (6%), were designated as high
risk (24% overall).
Proximal anastomoses arose from the common femoral
artery in 49%, the superficial femoral artery in 25%, and the
popliteal artery in 18% of patients. Distal anastomoses were
performed primarily to tibial vessels (53%); 33% were per-
formed to popliteal and 12% to pedal targets. Procedural
details are summarized in Table II. There were no signifi-
cant differences between the study arms.
Review of relevant medications being taken by subjects
at study entry revealed that 67% were receiving antiplatelet
agents (including aspirin in 61% and thienopyridine drugs
in 17%) and that 20% were taking anticoagulant medica-
tions. In total, 76% of patients were taking some antithrom-
botic drug at the time of entry into PREVENT III. Lipid-
lowering drugs were taken by 46% of patients and -blockers
were taken by 48% at baseline. There were no significant
differences in use of these medications between the edifo-
ligide and placebo treatment arms. A detailed analysis of
factors related to the use of cardioprotective medications in
PREVENT III is reported elsewhere.16
Adherence to the protocol-specified ultrasound surveil-
lance schedule was achieved in a high percentage of pa-
tients. Overall, 98% of eligible grafts were imaged at least
once by duplex scan. Compliance at each of the individual
study windows was 92% at 1 month, 83% at 3 months, 85%
at 6 months, and 62% at 12 months.
Early (30-day) adverse postoperative events.
Perioperative (30-day) mortality for the entire trial cohort
Table II. Characteristics of procedures performed
Variable
Edifoligide
(n  707)
Placebo
(n  697)
Reoperative bypass 124 (17.5%) 106 (15.2%)
Conduit type
Single segment GSV, reversed 371 (52%) 360 (52%)
Single segment GSV,
nonreversed 207 (29%) 193 (28%)
Spliced vein 95 (13%) 110 (16%)
Single segment non-GSV 34 (5%) 34 (5%)
Vein diameter 3 mm 36 (5.1%) 49 (7.0%)
Total high-risk conduits 158 (22%) 181 (26%)
Proximal anastomosis
Common femoral 352 (50%) 335 (48%)
Superficial femoral 164 (23%) 184 (26%)
Deep femoral 39 (6%) 41 (6%)
Popliteal 129 (18%) 118 (17%)
Other 23 (3%) 19 (3%)
Distal anastomosis
Popliteal, above knee 69 (10%) 76 (11%)
Popliteal, below knee 161 (23%) 151 (22%)
Anterior tibial 106 (15%) 113 (16%)
Posterior tibial 136 (19%) 154 (22%)
Peroneal 132 (19%) 107 (15%)
Pedal/plantar 80 (11%) 86 (12%)
Other 17 (2%) 10 (1%)
GSV, Great saphenous vein.
All data are n (%); P  not significant.was 38 patients (2.7%). Major complications (Table III)
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cerebrovascular event (stroke or transient ischemic attack)
in 20 (1.4%). Early occlusion of the index graft occurred in
73 (5.2%) patients. There were no significant differences in
early adverse postoperative events between the study treat-
ment groups. The PK substudy demonstrated that serum
levels of edifoligide were not detectable in most patients
and that if they were detectable in the highly sensitive assay
used, they were generally only slightly above the lower level
of detection (2 ng/mL).
Protocol-specified study end points. The primary
study end point, a Kaplan-Meier estimate of nontechnical
index graft failure, was observed in 356 (25.4%) patients in
the trial, with no significant difference noted between the
edifoligide (25.2%) and placebo (25.5%) study arms (Fig 1, A).
The other protocol-specified end points (Table IV and
F i g 1 ) , including Kaplan-Meier estimates at 12 months of
all-cause clinical failure (34.8% vs 36%), freedom from
clinically significant index graft stenosis (44.3% vs 46.1%),
nontechnical primary index graft patency (70.7% vs 70.7%),
and amputation/reintervention-free survival (50.1% vs
48.6%) also failed to demonstrate a significant treatment
effect.
Graft patency, limb salvage, and patient survival.
For the overall trial cohort, primary, primary assisted, and
secondary graft patency rates (as conventionally defined14)
were 61%, 77%, and 80%, respectively. Comparison be-
tween the study arms revealed no significant difference in
primary or primary assisted graft patency (Table IV and Fig 2).
However, a significant improvement in secondary graft
patency was noted in the edifoligide group (83% vs 78%;
P .016). A significant difference in secondary patency was
manifest within 30 days of surgery (relative risk of 30-day
event for edifoligide group, 0.45; 95% confidence interval,
Table III. Postoperative (30-day) complications
Variable Edifoligide Placebo Total
Total major morbidity 123 (17.4%) 124 (17.8%) 247 (17.6%)
Cardiac or
respiratory arrest 12 (1.7%) 9 (1.3%) 21 (1.5%)
DVT 6 (1.0%) 8 (1.1%) 14 (1.0%)
Death 20 (2.8%) 18 (2.6%) 38 (2.7%)
Graft occlusion 30 (4.2%) 43 (6.2%) 73 (5.2%)
Major amputation 13 (1.8%) 12 (1.7%) 25 (1.8%)
Myocardial infarction 33 (4.7%) 33 (4.7%) 66 (4.7%)
Pneumonia 10 (1.4%) 13 (1.9%) 23 (1.6%)
Pulmonary embolism 1 (1.0%) 0 (0.0%) 1 (1.0%)
Stroke/TIA 12 (1.7%) 8 (1.1%) 20 (1.4%)
Major wound
complication 37 (5.2%) 30 (4.3%) 67 (4.8%)
Dehiscence 3 (1.0%) 9 (1.3%) 12 (1.0%)
Infection 24 (3.4%) 15 (2.2%) 39 (2.8%)
Necrosis 9 (1.3%) 6 (1.0%) 15 (1.1%)
Unknown 1 (1.0%) 0 (0.0%) 1 (1.0%)
Graft Hemorrhage 3 (0.4%) 3 (0.4%) 6 (0.4%)
DVT, Deep venous thrombosis; TIA, transient ischemic attack.
All data are n (%); P  not significant.0.27-0.76; P  .005; Fig 2, C).Several post hoc subgroup analyses were performed to
evaluate for potential drug effects. Among high-risk grafts
(defined as a diameter 3 mm, a spliced vein, or a non–
great saphenous vein conduit), primary (42% vs 46%),
primary assisted (63% vs 64%), and secondary (71% vs 67%)
patency outcomes were not different between treatment
groups. No significant treatment effects could be discerned
when outcomes were evaluated separately in diabetic pa-
tients or for reoperative graft procedures or when the
operations were stratified by mode of presentation, distal
outflow target, or graft length. Patient survival (84%) and
limb salvage (88%) were not significantly different between
the two treatment groups (Table IV; Fig 2, D and E).
Nature of graft lesions and types of reinterventions
performed. We attempted to evaluate the overall burden
of vein graft disease by examining the nature of lesions that
required reintervention and the types of procedures per-
formed (Table V). Of grafts that underwent any reinterven-
tion during the study period, 70% had a single revision, 22%
had two, and 8% had three or more; the proportions were
nearly identical in both study arms. The first graft reinter-
vention was a percutaneous angioplasty or open patch in
56%; a jump or interposition graft in 16%; and a thrombec-
tomy, thrombolysis, or the creation of an entirely new graft
in 28.5%. In this post hoc analysis, there were 73 patients in
the placebo group who had thrombectomy, thrombolysis,
or an entirely new graft placed as their first reintervention, in
comparison to 51 in the edifoligide group (P .040; 2).We
also analyzed data from the ultrasonography preceding the
first reintervention and compared the number of graft
lesions identified. In 57% of cases, a single lesion had been
identified, whereas in 20% there were two; no significant
difference was found in the number of lesions according to
treatment group.
DISCUSSION
The PREVENT III trial was well powered to test its
primary hypothesis, with a randomized population of more
than 1400 subjects; hence, the results of the study are
unambiguous. The data clearly demonstrate that edifoli-
gide treatment did not reduce the incidence of vein graft
reintervention or the development of significant stenoses in
a large cohort of patients undergoing infrainguinal recon-
struction for CLI. However, although none of the protocol-
specified study end points was met in the edifoligide arm, a
significant improvement in graft secondary patency was
observed. The risk reduction observed (5% absolute and
19% relative reduction in secondary patency events) seems
to suggest some beneficial biological effect of the therapy
that merits further inspection.
The improvement in secondary patency observed in the
edifoligide group, in the absence of any observed effect on
primary graft patency or the occurrence of clinically signif-
icant stenosis, was unexpected and raises important ques-
tions about the presumed biologic effects of the drug, as
well as the relationship between the process presumably
being targeted (intimal hyperplasia) and the clinical end
points measured. Possible explanations for the observed
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inflammatory properties of the drug. It is also possible that
the secondary patency benefit relates to a reduction in the
virulence of the hyperplastic process, which in its most
severe form could result in rapidly progressive or unher-
alded occlusions. The secondary patency benefit is also re-
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Fig 1. Analysis of protocol-specified end points by the K
study end point: nontechnical index graft failure. B, All-c
index graft stenosis. D, Event-free survival.
Table IV. Summary of outcomes at 1 year (all data
reported as Kaplan-Meier estimated percentages)
Variable Edifoligide Placebo P value
Protocol-specified end points
Primary trial end point
(nontechnical failure) 25.2 25.5 .69
All clinical failures 34.8 36 .51
Freedom from clinically
significant stenosis 44.3 46.1 .62
Amputation/
reintervention-free
survival 50.1 48.6 .47
Conventional end points
Primary patency 61.5 59.5 .38
Primary assisted patency 78.6 74.7 .10
Secondary patency 82.6 77.5 .02
Limb salvage 87.7 89.2 .37
Survival 83.2 84.4 .55flected in the nature of the first intervention, as presented inTable V. Of course, the possibility that this statistically signif-
icant finding occurred by chance alone and would not be
replicated if the trial were repeated must also be considered.
Prevention of amputation or graft reintervention was
rightfully selected as the primary study end point in
PREVENT III, because it directly relates to patient mor-
bidity. However, these end points very likely do not accu-
rately reflect the overall burden of proliferative disease
within the graft, because a very focal lesion treatable by
patch angioplasty and a long severe stricture requiring
extensive graft replacement were counted equally as end
points. We examined the number of lesions observed by
ultrasonography, the number of reinterventions per-
formed, and the magnitude of the reinterventions per-
formed as potential surrogates for graft disease burden;
however, each of these measures has limitations. Intravas-
cular ultrasonography has been used effectively for this
purpose in coronary artery and vein graft disease and was
used in PREVENT II; however, the technique is costly and
invasive and adds real potential risk in the lower extremity
setting. Lacking a better surrogate measure of graft intimal
hyperplasia, we are ultimately unable to discriminate be-
tween an incorrect target (E2F specifically or SMC prolif-
eration in general) or ineffectiveness of the therapy to block
the target as an explanation for the failure of edifoligide to
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April 2006748 Conte et alPREVENT III was a novel trial in multiple respects. It
constitutes the largest prospective, randomized study of
vein bypass for advanced lower extremity ischemia per-
formed to date, and the overall surgical results will stand as
a benchmark for current practice. The population studied
was restricted to CLI specifically because traditionally re-
ported failure rates have been higher than in claudicants
and also because this population was believed to have the
most potential gain from a beneficial therapy. In addition,
study entry criteria were intentionally set to be broad, thus
allowing the enrollment of patients requiring complex re-
operative procedures as well as those with advanced comor-
bid conditions (eg, dialysis-dependent renal failure). The
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Fig 2. Outcomes at 1 year by the Kaplan-Meier metho
assisted graft patency (P  not significant). C, Secondar
(P  not significant). E, Patient survival (P  not signifistudy population thus truly reflects the current practice oflimb salvage surgery, with its inherent medical and surgical
complexities, complications, and mortality. In this context,
the perioperative mortality (2.7%) and graft occlusion
(5.2%) rates observed in PREVENT III compare well to
those of retrospective single-center series. This attests to
the high standard of care provided by the participating
investigators and centers. Furthermore, the 1-year out-
comes of 84% survival, 80% secondary patency, and 88%
limb salvage are well within the expected range for patients
with CLI.
These data suggest that treatment of the vein ex vivo
with edifoligide in the pressurized drug-delivery systemwas
well tolerated. The drug-delivery parameters used (concen-
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Volume 43, Number 4 Conte et al 749clinical testing for optimization of ODN transfection into
veins.17 Device training was provided to all investigators in
the study. Nonetheless, there remains a possibility that
incorrect or inappropriate use of the device could have led
either to inadequate drug delivery or to inadvertent damage
to the vein. No vein graft samples were taken in this trial to
verify that adequate drug was delivered or to examine the
biological effects of drug treatment (eg, target gene inhibi-
tion or cell proliferation), as was done in the PREVENT I
study.11 Furthermore, in PREVENT III, grafts in the con-
trol arm were also treated with pressurization in the device,
to ensure complete blinding as to study drug treatment.
Prior phase I and II investigations had not demonstrated an
apparent adverse effect of vein exposure to nondistending
pressure of this nature; however, formal testing would have
required a three-arm study to include standard intraopera-
tive handling of the vein. Because there are no comparable
large, multicenter, prospective studies in this population,
we are unable tomake a definitive comment on whether the
handling of vein grafts in the placebo arm had any effects on
outcome. However, early graft thrombosis/reintervention
rates in PREVENT III were well within the range of prior
retrospective reports, and the Data Safety Monitoring
Board (which reviewed study data at three prespecified
intervals) overseeing the trial confirmed a lack of safety
concerns. The use of this system or similar systems to
efficiently deliver small oligonucleotides (or other mo-
lecular agents) locally to veins ex vivo has great attrac-
tiveness for intraoperative therapies, and the feasibility of
such an approach has been definitively established by
PREVENT III.
In addition to the points already mentioned, there are
some other relevant limitations to this study. Graft surveil-
lance studies were performed and interpreted at the indi-
vidual sites, in accordance with local vascular laboratory
procedures. All study sites used fully accredited vascular
Table V. Nature of treated graft lesions and reinterventio
Variable
Total number of reinterventions per graft
One
Two
Three or more
Nature of first reintervention*
PTA or patch angioplasty
Jump or interposition graft
Thrombectomy/thrombolysis or new graft†
Number of significant lesions via prior ultrasonography‡
Zero
One
Two
Three or more
PTA, Percutaneous transluminal angioplasty.
All data are presented as the number (%) of patients, where the denominator
*Excludes amputations.
†P  .04, 2; all other comparisons are not significant.
‡Ultrasound findings on the most recent study before the first graft reintervlaboratories. A central core laboratory was not used forreview of imaging studies in PREVENT III. Because sur-
veillance studies lead directly to reinterventions, variability
in patient compliance or in the performance of these studies
could have direct effects on study end points. Nonetheless,
the study was executed in the fashion that most mirrors
clinical practice, and randomization would be expected to
balance any local variability in reintervention rates. Along
similar lines, mandating a standardized approach to con-
comitant medical therapy would offer scientific advantages
but would require major changes in the local and individual
practice settings.
Recently reported results from PREVENT IV, the
phase III trial of edifoligide vs placebo in 3000 patients
undergoing coronary artery vein bypass graft procedures,
also demonstrated the absence of a drug effect on any of the
primary or secondary end points.18 These two large phase
III trials of edifoligide were based largely on data from two
prior single-center phase I and II trials: one in the lower
extremity and one in the coronary circulation. Because of
the wide variability in surgical technique and in the geo-
graphic variability of surgical patient populations, it seems
prudent to recommend that phase III surgical trials be
based on multicenter phase II experience if at all possible.
In conclusion, this prospective, randomized clinical
trial failed to demonstrate a reduction in vein graft failure in
CLI patients treated with a single ex vivo administration of
a novel molecular agent, edifoligide. Although the primary
results are disappointing, PREVENT III has demonstrated
that large multicenter trials of an intraoperative genetic
intervention designed to modulate the vascular injury re-
sponse can be executed safely and with high surgical and
scientific quality. It is hoped that future investigations,
informed by the design and outcomes of this study, will
continue to explore targeted molecular therapies to im-
prove outcomes for patients undergoing vascular recon-
Edifoligide Placebo Total
62 (70.7%) 160 (69.6% 322 (70.2%)
52 (22.7%) 49 (21.3%) 101 (22.0%)
15 (6.6%) 21 (9.1%) 36 (7.8%)
23 (57.2%) 118 (53.9%) 241 (55.6%)
41 (19.1%) 28 (12.8%) 69 (15.9%)
51 (23.7%) 73 (33.4%) 124 (28.5%)
38 (16.2%) 41 (17.9%) 79 (17.0%)
30 (55.3%) 135 (59.0)% 265 (57.1%)
54 (23.0%) 20 (17.5%) 94 (20.3%)
13 (5.6%) 13 (1.3%) 26 (1.1%)
s soley of those that underwent an index graft reintervention or amputation.
n.ns
1
1
1
consiststructions.
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Dr Frank LoGerfo (Boston, Mass). I think you can argue that
this is the most accurate outcome study of lower extremity vein
grafts, certainly in my career in vascular surgery, where we have
such detailed duplex study outcomes in every patient, including
the 1-month outcome. I wonder if this trial is really a failure in the
sense that a 20% improvement in secondary patency is certainly, in
the long run, what we are most concerned about. And I’m won-
dering, then, what about that first month where those are purely
technical failures. If you take that out of the picture, how does it
look? And finally, you have dozens of interesting risk factors here
that you could relate to outcome. Are you prepared and capable of
further analyzing these data, which are so extraordinarily valuable?
Dr Conte. Thank you, Dr LoGerfo. We certainly appreciate
the support of your institution in this study as our leading enroller.
As you point out, the secondary patency effect was significant. And,
in fact, a prevention of secondary events in one out of five patients
seems like a fairly good result. As you might expect, the primary
difference between the groups was in the frequency of abandoned
grafts. It turns out that the early difference in secondary patency issecondary patency curves are still different. We’re not sure what to
ascribe this to. It’s possible that this drug has some other effects that
we don’t know about, such as effects on thrombosis or inflammation,
that might explain some of this. The subgroup analyses, as you know,
have been ongoing, and we have looked at some things. What I can
tell you, to date, is that there did not appear to be an enhancement of
effect, for example, in high-risk grafts, diabetic patients, or any of the
categories that we’ve looked at thus far. We have not boiled out a
subgroup that really showed an enhanced drug effect. There is still a
lot of work to be done in this database, and we hope to be able to do
that over the next few months.
Dr Alan Dardik (New Haven, Conn). Even though the
results of the primary intervention were not dramatic, the
importance of establishing that molecular therapy is safe, is
important in our literature. Two questions. First, did you or any
of the investigators have the opportunity to examine these grafts
in follow up with IVUS [intravascular ultrasound] and, perhaps,
examine the intima-media ratios of these grafts? I think that
some of your preliminary reports indicated that changing the
I-to-M [intima-media] ratios were an important benefit of this
JOURNAL OF VASCULAR SURGERY
Volume 43, Number 4 Conte et al 751drug. And second, I’m wondering, how does this result com-
pare with some of the previous results of the cardiac trials? Do
they imply anything for us?
DrConte.As you can see from the last bit of what I presented,
we have been struggling with trying to get a measure, a surrogate
measure, of intimal hyperplasia in the graft. I agree with you that
one of the best ways that I could think of doing that would be
IVUS. It was not done in this study, and I think it is actually
considerably more difficult to accomplish in the lower extremity as
compared to in the coronary circulation where you’re not actually
puncturing the graft. But I think it would have been quite valuable
to have a measure of total graft wall thickening. Unfortunately, we
don’t have that type of data in this study. In regard to the cardiac
trial results, all I can say about that is what’s been said publicly in
the press release, which is that PREVENT IV was also negative in
terms of the primary study end points. They are also doing many
other analyses in their database and will be presenting their data
very shortly.
Dr Thomas Lindsay (Toronto, Ontario, Canada). I wanted
to ask, as an investigator, how do we know that we actuallydelivered the drug to the vein grafts equally across so many
investigational sites? As you know, pressurizing the device was
subject to a little bit of error, I would imagine, despite the fact that
we’d all been trained. So how do we know that we actually
delivered the drug appropriately?
Dr Conte. It’s a terrific question and one that we continue to
wonder about. And I can only give you a partial answer. What was
recorded by study monitors were gross problems with drug deliv-
ery in the operating room if, for example, the device didn’t
function or there was some other mishap in drug handling. That
turned out to be a very, very small number of cases. So, of course,
we’re left with several possibilities, including the possibility that the
molecular target was wrong or the possibility that that target is
right but was inadequately treated by the drug either because of the
variability in delivery or perhaps the mode of a single delivery. We
just don’t know how to discriminate those at the present time.
Having said that, all the centers had training with the device, as you
know, including either on-site training or a video, and it’s a fairly
simple device to use.
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INVESTIGATOR LIST BY ENROLLMENT
Alan Hamdan, MD (Boston, Mass); 77 patients
Sean Roddy, MD (Albany, NY); 68 patients
Scott Berceli, MD (Gainesville, Fla); 67 patients
David Cossman, MD (Los Angeles, Calif); 64 patients
William H’Doubler, MD (Roanoke, Va); 60 patients
James McNeil, MD (Baton Rouge, La); 52 patients
Dennis Bandyk, MD (Tampa, Fla); 49 patients
Michael Conte, MD (Boston, Mass); 48 patients
Scott Berman, MD (Tucson, Ariz); 42 patients
John Eidt, MD (Little Rock, Ark); 40 patients
Gregory Moneta, MD (Portland, Ore); 36 patients
Russell Samson, MD (Sarasota, Fla); 36 patients
Silverio Cabellon, MD (Washington, DC); 35 patients
Richard DeMasi, MD (Norfolk, Va); 34 patients
Ralph Pfeiffer, MD (Mobile, Ala); 32 patients
Robert Hye, MD (San Diego, Calif); 27 patients
David Mozersky, MD (San Antonio, Tex); 27 patients
Victoria Teodorescu,MD (New York, NY); 26 patients
Roman Nowygrod, MD (New York, NY); 25 patients
Charles Shanley, MD (Royal Oak, Miss); 24 patients
Mark Davies, MD (Rochester, NY); 22 patients
Andrew Hill, MD (Ottawa, Ontario, Canada); 22 pa-
tients
William Bogey, MD (Greenville, NC); 20 patients
Edith Tzeng, MD (Pittsburgh, Pa); 20 patients
David Han, MD (Hershey, Pa); 19 patients
Kenneth Harris, MD (London, Ontario); 19 patients
Richard Powell, MD (Lebanon, NH); 19 patients
Jeffrey Martinez, MD (San Antonio, Tex); 18 patients
Michael Dalsing, MD (Indianapolis, Ind); 17 patients
Randy Guzman, MD (Winnipeg, Manitoba); 17 patients
Alan Lumsden, MD (Houston, Tex); 16 patients
Elliott Chaikof, MD (Atlanta, Ga); 14 patients
Paul Gagne, MD (New York, NY); 14 patients
Ronald Dalman, MD (Palo Alto, Calif); 12 patients
William Edwards, Jr, MD (Nashville, Tenn); 12 patients
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Thomas Brothers, MD (Charleston, SC); 11 patients
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Thomas Rehring, MD (Denver, Colo); 5 patients
Jodi Spelay, MD (Saskatoon, Saskatchewan, Canada);
5 patients
Tina Desai, MD (Chicago, Ill); 4 patients
William Jordan, MD (Birmingham, Ala); 3 patients
Audra Noel, MD (Rochester, Minn); 3 patients
David Drezner, MD (Hartford, Conn); 2 patients
Michael Golden, MD (Philadelphia, Pa); 2 patients
Michael Lilly, MD (Baltimore, Md); 2 patients
Craig Kent, MD (New York, NY); 1 patient
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